Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,773 across all filing types
Latest filing 2024-06-10 AGM Information
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Evotec SE: Results of the Annual General Meeting 2024
AGM Information Classification · 1% confidence The document explicitly states in the title and content: "Evotec SE: Results of the Annual General Meeting 2024". It details the outcomes of shareholder votes, the election of new Supervisory Board members, and the discharge of liability for board members, which are all core components of an Annual General Meeting (AGM) outcome announcement. This directly corresponds to the definition for AGM Information (AGM-R). Although it mentions voting results, the primary focus is the overall meeting results and governance changes, making AGM-R the most precise fit over DVA (Declaration of Voting Results & Voting Rights Announcements), which is usually narrower.
2024-06-10 English
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables reporting changes in share ownership ('Notification of Major Holdings') by a legal entity (T. Rowe Price Group, Inc.) in Evotec SE, referencing specific German securities law articles (WpHG). This directly corresponds to the definition of a Major Shareholding Notification, which tracks changes in significant ownership thresholds. The code for this is MRQ.
2024-06-04 English
Declaration of Corporate Management 2023
Governance Information Classification · 1% confidence The document is a 'Declaration on corporate governance' for the financial year 2023, explicitly citing Sections 289f and 315d of the German Commercial Code (HGB). It details the company's compliance with the German Corporate Governance Code, describes the working practices of the Management and Supervisory Boards, and outlines board composition and diversity policies. This content is characteristic of a Corporate Governance Report, which falls under the 'Governance Information' category.
2024-06-01 English
Erklärung zur Unternehmensführung 2023
Governance Information Classification · 1% confidence The document is titled "Erklärung zur Unternehmensführung für das Geschäftsjahr 2023 (§§ 289f, 315d HGB)" and contains an "Entsprechenserklärung zum Deutschen Corporate Governance Kodex gemäß § 161 AktG für das Geschäftsjahr 2023". It details the company's corporate governance structure, compliance with the German Corporate Governance Code, and descriptions of the roles and composition of the Management Board (Vorstand) and Supervisory Board (Aufsichtsrat). This content directly relates to the company's internal rules, board structure, and governance practices, which aligns perfectly with the definition of Governance Information (CGR). The length (80,003 chars) confirms it is a detailed report, not just an announcement (RPA/RNS).
2024-06-01 German
Remuneration Report 2023 of Evotec SE
Remuneration Information Classification · 1% confidence The document is explicitly titled "Remuneration report 2023 for Evotec SE". It details the remuneration awarded and owed to the Management Board and Supervisory Board members for the financial year 2023, referencing German corporate law (AktG) and the German Corporate Governance Code (GCGC). It discusses basic salary, ancillary benefits, and performance-related variable remuneration components. This content directly aligns with the definition of a Remuneration Information document, which corresponds to the DEF 14A code in the provided schema, as this document details compensation for top executives and directors. Although the document discusses approval at the AGM, the core content is the remuneration details itself, not the AGM materials or voting results.
2024-06-01 English
Company Presentation June 2024 (English)
Investor Presentation Classification · 1% confidence The document is explicitly titled "General company presentation" and contains slides with section headers like "About us," "Shared R&D," "Just Evotec Biologics," and a detailed pipeline overview dated "June 2024." It includes forward-looking statements, scientific details, and a pipeline status table referencing data as of December 31, 2023. This structure is characteristic of an Investor Presentation (IP) designed to communicate strategy, performance, and pipeline status to investors, rather than a formal regulatory filing (like 10-K or IR) or a brief announcement (like ER or RPA).
2024-06-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.